Pembrolizumab NHS Injection 2026: Cancer Treatment Time Cut from Two Hours to One Minute

NHS England rolled out the 1 to 2 minute pembrolizumab subcutaneous injection on 6 May 2026, replacing a 30 minute IV drip for 14 cancer types.

You turn up for your tenth pembrolizumab cycle for triple negative breast cancer. The day usually means cannula, drip and a long wait. This time your oncology nurse offers a one minute injection under the skin instead. That is the reality from May 2026, after NHS England announced the rollout of Keytruda Qlex, the subcutaneous form of pembrolizumab, on 6 May 2026. The active drug is unchanged. What changes is how it is delivered. The shift from a 30 minute IV infusion plus the waiting around to a 1 to 2 minute under-the-skin injection takes the chair time down by up to 90 percent. Most of the 14,000 NHS patients in England who start pembrolizumab each year, across its 14 licensed cancer indications, will benefit. This guide walks through how the injection works, what it means for your treatment day, side effects, and what to ask your oncology team.

What is the new pembrolizumab injection and when did the NHS start using it

The NHS in England began rolling out the subcutaneous pembrolizumab injection on 6 May 2026. The first NHS patient was 89 year old Shirley Xerxes at Mount Vernon Cancer Centre, treated for triple negative breast cancer. The product is Keytruda Qlex, made by Merck Sharp and Dohme. It combines the existing pembrolizumab antibody with an enzyme called berahyaluronidase alfa-pmph. The enzyme briefly opens up the tissue under the skin so a small, concentrated volume of the drug can be injected without an intravenous line. The injection takes about 1 minute if given every 3 weeks, or about 2 minutes on a 6 weekly schedule. The regulatory path: FDA approval 19 September 2025, an EMA positive opinion in September 2025, MHRA UK authorisation in early 2026, and the NHS England commissioning policy in May 2026. The rollout is starting in major cancer centres and will expand to most eligible patients over the coming months. The drug inside is the same pembrolizumab, so response rates, the core side effect profile and your monitoring intervals do not change. What changes is the delivery method, the time in the chair and the overall patient experience.

How the injection compares with the IV infusion

The practical time difference is large. A standard IV pembrolizumab session runs from arrival, blood tests, clinician review, cannula insertion, 30 minute infusion, post-infusion observation and cannula removal. Total chair time is typically 90 minutes to 2 hours. The subcutaneous injection session is shorter: arrival, blood tests, clinician review, 1 to 2 minute injection, brief observation. Total clinic time is typically 30 to 45 minutes. So the per-cycle saving is 60 to 90 minutes. Across a typical 18 cycle course that is 18 to 27 hours of patient time returned. Patient feedback and trial data both lean towards the subcutaneous route when efficacy is equal. Reasons cited: shorter visits, no cannula, no risk of drug extravasation, less wear on veins for routine blood draws, more flexibility for life outside the clinic. The phase 3 trial 3475A-D77 in metastatic non small cell lung cancer showed the subcutaneous form has non-inferior blood drug levels, comparable efficacy and a comparable safety profile compared with IV. The trade-off is small. The injection can cause local site reactions like redness or soreness; the IV is more likely to cause infusion related reactions like fever, chills or rare allergic events. For most stable patients, the injection is a clear win.

Which cancers the NHS pembrolizumab injection covers

The subcutaneous formulation is licensed for the same 14 cancer indications as the IV product. That covers: melanoma (advanced and high-risk adjuvant after surgery); non small cell lung cancer (first line and beyond); small cell lung cancer; head and neck squamous cell carcinoma (recurrent or metastatic, and from NICE final draft guidance on 24 March 2026 also resectable locally advanced disease); classical Hodgkin lymphoma; primary mediastinal large B cell lymphoma; urothelial carcinoma (bladder and urinary tract); microsatellite instability high or mismatch repair deficient solid tumours; gastric (stomach) cancer; oesophageal cancer; cervical cancer; triple negative breast cancer (early and metastatic); endometrial (womb) cancer; renal cell (kidney) cancer. The full list is in the MHRA Summary of Product Characteristics for Keytruda Qlex. Around 14,000 NHS patients in England start pembrolizumab each year across these indications. Most will be eligible for the subcutaneous route. Each cancer centre will sequence the switch based on local capacity and individual suitability. If you are on IV pembrolizumab now, ask your oncology team about switching at your next cycle review.

Side effects and what to watch for

The common side effects of pembrolizumab are the same regardless of how it is given. They include fatigue, skin rash, diarrhoea, nausea, decreased appetite, joint pain, itching and cough. Route specific differences are small. The subcutaneous injection can cause local reactions at the site (redness, soreness, swelling) that usually settle within a few days. The IV was more likely to cause infusion related reactions like fever, chills or occasional allergic responses during the drip. Pembrolizumab works by releasing a brake on the immune system, which can lead to immune mediated side effects in any organ. Know the key warning signs. Pneumonitis (lung inflammation) presents as a new cough or shortness of breath. Colitis (bowel inflammation) shows up as diarrhoea more than 4 stools above your usual, abdominal pain, or blood in the stool. Hepatitis (liver inflammation) can cause jaundice, severe fatigue, or abnormal liver function tests. Endocrinopathies are common in long term users: thyroid changes are usually picked up on routine bloods, while pituitary or adrenal insufficiency can present as profound fatigue, low blood pressure or low sodium. Myocarditis (heart inflammation) is rare but serious and can cause chest pain, breathlessness or palpitations. Everyone on pembrolizumab should know how to contact their cancer centre acute oncology service and have the 24 hour helpline number to hand. Regular monitoring blood tests continue unchanged.

What changes for patients already on IV pembrolizumab

If you are on a stable course of IV pembrolizumab, you can ask about switching to the subcutaneous injection at your next cycle review. Clinical efficacy is identical. The conversation will cover suitability, local availability, scheduling and your own preference. Most patients will be eligible. Some may choose to stay on IV: people with a port-a-cath already in place for other treatments, anyone who needs IV access for other supportive therapies during their visit, or those with a history of significant subcutaneous injection reactions. The decision is shared. Practical tips for your first injection appointment: wear loose clothing that gives access to the upper thigh or abdomen, where the injection is usually given. Expect a brief sting or pressure for 1 to 2 minutes. Some redness or soreness at the site afterwards is normal and settles in a few days. Routine monitoring bloods and tumour response scans (CT, MRI, PET) continue at exactly the same intervals. The drug is the same, so the response rates are the same. Keep using the acute oncology helpline for any new symptoms (cough, breathlessness, persistent diarrhoea, jaundice, severe fatigue).

What this means for the NHS productivity programme

NHS England estimates that switching most pembrolizumab patients from IV to subcutaneous will free tens of thousands of chemotherapy chair hours across the service each year. That is a real operational gain. Each freed chair hour can go to other patients on cancer treatments: chemotherapy, other IV immunotherapies, blood transfusions, IV antibiotics, clinical trial visits. The change is a piece of the wider NHS Long Term Plan productivity programme, and one of the rarer cases where the productivity gain also improves the patient experience. Looking forward, the subcutaneous route opens up the possibility of delivery closer to home: community clinics, or even home with a visiting nurse. NHS England is starting with major cancer centres for quality and safety oversight. The model is similar to the trastuzumab (Herceptin SC) breast cancer switch from a decade earlier. If this pembrolizumab rollout goes smoothly, expect subcutaneous nivolumab and atezolizumab to follow as those products move through approval. The medicine inside does not change. The way it is delivered does, and for both patients and the workforce the difference is material.

Frequently Asked Questions

How long does the pembrolizumab injection take

The injection itself takes about 1 minute when given every 3 weeks, or about 2 minutes every 6 weeks. Total clinic time, including blood tests, clinician review and a brief observation, is typically 30 to 45 minutes. The IV pembrolizumab infusion involved a 30 minute drip plus cannulation and observation, often totalling 90 minutes to 2 hours of chair time per cycle.

Is the injection as effective as the IV drip

Yes. The active drug is the same pembrolizumab antibody. The phase 3 trial 3475A-D77 in metastatic non small cell lung cancer showed the subcutaneous form has non-inferior blood drug levels, comparable efficacy and a comparable safety profile to the IV form. Scan response rates and progression free survival data are consistent between routes. Monitoring intervals do not change.

Which cancers does the NHS pembrolizumab injection cover

All 14 cancers that IV pembrolizumab is licensed for: melanoma, non small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma (including locally advanced disease per NICE guidance from March 2026), classical Hodgkin lymphoma, primary mediastinal large B cell lymphoma, urothelial carcinoma, MSI-H or dMMR solid tumours, gastric, oesophageal, cervical, triple negative breast cancer, endometrial and renal cell carcinoma.

Can I switch from IV pembrolizumab to the injection

Most patients can. Speak to your oncology team at your next appointment. The switch is a shared decision based on suitability, local availability and your preference. Most NHS centres began offering it from May 2026. Some patients, such as those with an existing port-a-cath, may choose to stay on the IV infusion.

What are the side effects of the injection

Common side effects are the same as the IV drip: fatigue, rash, diarrhoea, nausea, joint pain and cough. The injection can cause temporary redness, soreness or swelling at the site. It is less likely to cause fever or chills than the IV. Serious immune related side effects can still happen, so contact your oncology team urgently for any new cough, breathlessness, persistent diarrhoea or jaundice.

Is the pembrolizumab injection available privately in the UK

Private oncology clinics in the UK are expected to offer Keytruda Qlex from late 2026. Private cost is likely to be similar to private IV pembrolizumab, typically several thousand pounds per cycle. For NHS patients the treatment is free at the point of delivery, under the existing confidential pricing agreement between NHS England and Merck Sharp and Dohme.

Will I still need regular blood tests and scans

Yes. Changing how the drug is given does not change your monitoring plan. You will continue with full blood count, liver and kidney function, thyroid function and any tumour specific tests at the same intervals. Tumour response scans (CT, MRI or PET) continue as before. The acute oncology helpline is unchanged. Report new symptoms (cough, breathlessness, diarrhoea, jaundice, severe fatigue) urgently.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.